Urothelkarzinom: Atezolizumab in den USA als Zweitlinientherapie zugelassen
- PMID: 30731499
- DOI: 10.1055/s-0043-116166
Urothelkarzinom: Atezolizumab in den USA als Zweitlinientherapie zugelassen
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Comment on
-
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.Oncologist. 2017 Jun;22(6):743-749. doi: 10.1634/theoncologist.2017-0087. Epub 2017 Apr 19. Oncologist. 2017. PMID: 28424325 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
